Ian J. Clifton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ian J. Clifton has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Peckham
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
8 shared publications - Giulia Spoletini
The Leeds Regional Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK
6 shared publications - Christine Etherington
Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom
4 shared publications - Akhil Sawant
Leeds Regional Adult CF Centre, Department of Respiratory Medicine, Leeds Teaching Hospital NHS Trust, Leeds, UK
2 shared publications Christine Etherington
Leeds Regional Adult CF Centre, Department of Respiratory Medicine, Leeds Teaching Hospital NHS Trust, Leeds, UK
2 shared publicationsHassan Burhan
Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Open Quality
- Vol. 15 (3) , e004112
Development of the UK Severe Asthma Registry as a performance-monitoring quality improvement platform
The UK Severe Asthma Registry (UKSAR) was established to facilitate research and quality improvement including performance monitoring across UK severe asthma centres. We here describe its development and refinement for the latter of those objectives. The selection of performance outcome measures for severe asthma clinical outcomes from clinician and patient perspectives, data collection and assessment of clinical variation across severe asthma centres is described. We report on the aim of UKSAR to assess for unwarranted clinical variation in those clinical outcomes between severe asthma centres and discuss the utility of UKSAR and associated registry meetings in addressing clinical variation and providing optimal severe asthma care. After stakeholder consultation, outcomes measures relating to exacerbations, oral corticosteroid exposure, asthma control and quality of life were selected with appropriate case-mix adjustment to help identify unexplained clinical variation. The registry data fields were then modified to collect the required data. Twice-yearly meetings of the registry steering committee were held to discuss data quality. Over 2018–2025 the number of participating centres increased from 17 to 42. To date, baseline data have been entered for 18 473 patients, with data meeting the agreed quality threshold for 12 792 patients. Analysis of variation in outcomes between centres, after case-mix adjustment and allowing for effect of centre size, shows relatively few examples of significant variation in outcomes between centres. Best-practice case studies from high-performing centres are presented. Twice-yearly discussion at registry meetings, attended by representatives from each severe asthma centre, of outcome measures and related research, together with sharing of best practice may explain the relatively low variation in clinical outcomes between centres. However, a limitation of UKSAR is that it cannot evaluate the presence and clinical impact of ‘hidden’ severe asthma not known to specialist services.
- 1 July 2026
- Published by BMJ in BMJ Open Quality
- Vol. 15 (3) , e004112
Open AccessDevelopment of the UK Severe Asthma Registry as a performance-monitoring quality improvement platform
The UK Severe Asthma Registry (UKSAR) was established to facilitate research and quality improvement including performance monitoring across UK severe asthma centres. We here describe its development and refinement for the latter of those objectives. The selection of performance outcome measures for severe asthma clinical outcomes from clinician and patient perspectives, data collection and assessment of clinical variation across severe asthma centres is described. We report on the aim of UKSAR to assess for unwarranted clinical variation in those clinical outcomes between severe asthma centres and discuss the utility of UKSAR and associated registry meetings in addressing clinical variation and providing optimal severe asthma care. After stakeholder consultation, outcomes measures relating to exacerbations, oral corticosteroid exposure, asthma control and quality of life were selected with appropriate case-mix adjustment to help identify unexplained clinical variation. The registry data fields were then modified to collect the required data. Twice-yearly meetings of the registry steering committee were held to discuss data quality. Over 2018–2025 the number of participating centres increased from 17 to 42. To date, baseline data have been entered for 18 473 patients, with data meeting the agreed quality threshold for 12 792 patients. Analysis of variation in outcomes between centres, after case-mix adjustment and allowing for effect of centre size, shows relatively few examples of significant variation in outcomes between centres. Best-practice case studies from high-performing centres are presented. Twice-yearly discussion at registry meetings, attended by representatives from each severe asthma centre, of outcome measures and related research, together with sharing of best practice may explain the relatively low variation in clinical outcomes between centres. However, a limitation of UKSAR is that it cannot evaluate the presence and clinical impact of ‘hidden’ severe asthma not known to specialist services.
- Open Access
- 1 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (179) , 250165
Physical inactivity in chronic airways disease: an important candidate in the treatable traits paradigm
Background: Physical inactivity is a common and potentially modifiable trait in individuals with chronic airways disease, yet disease-specific physical activity profiles and clinical determinants remain poorly defined. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines to characterise physical activity profiles across the spectrum of chronic airways disease. Studies reporting objectively measured physical activity in adults with COPD, asthma, noncystic fibrosis bronchiectasis, cystic fibrosis or primary ciliary dyskinesia were included. Primary outcomes were daily step count and time spent in moderate-to-vigorous physical activity (MVPA). Univariate and multivariate regression analysis was used to explore disease-specific determinants and associations with established clinical outcome measures. Results: 236 studies (353 cohorts, n=25 278 with chronic airways disease) met the eligibility criteria. The mean daily step count was 5494 (95% CI 5152–5636) and MVPA was 48.2 min·day −1 (95% CI 33.8–62.6), with the lowest levels observed in COPD. Physical activity levels were consistently lower than matched healthy controls. Disease-specific determinants of physical activity remained elusive; body mass index and percent predicted forced expiratory volume in 1 s (FEV 1 ) were significant in COPD and asthma. Step count associated positively with FEV 1 % pred and 6-min walk distance, and negatively with modified Medical Research Council scores. Conclusion: Physical inactivity is highly prevalent across chronic airways diseases and is consistently associated with established clinical outcome measures. These findings highlight the clinical relevance of objective physical activity assessment and support its consideration within the treatable traits framework as part of routine disease evaluation and management.
- 1 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (179) , 250165
Open AccessPhysical inactivity in chronic airways disease: an important candidate in the treatable traits paradigm
Background: Physical inactivity is a common and potentially modifiable trait in individuals with chronic airways disease, yet disease-specific physical activity profiles and clinical determinants remain poorly defined. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines to characterise physical activity profiles across the spectrum of chronic airways disease. Studies reporting objectively measured physical activity in adults with COPD, asthma, noncystic fibrosis bronchiectasis, cystic fibrosis or primary ciliary dyskinesia were included. Primary outcomes were daily step count and time spent in moderate-to-vigorous physical activity (MVPA). Univariate and multivariate regression analysis was used to explore disease-specific determinants and associations with established clinical outcome measures. Results: 236 studies (353 cohorts, n=25 278 with chronic airways disease) met the eligibility criteria. The mean daily step count was 5494 (95% CI 5152–5636) and MVPA was 48.2 min·day −1 (95% CI 33.8–62.6), with the lowest levels observed in COPD. Physical activity levels were consistently lower than matched healthy controls. Disease-specific determinants of physical activity remained elusive; body mass index and percent predicted forced expiratory volume in 1 s (FEV 1 ) were significant in COPD and asthma. Step count associated positively with FEV 1 % pred and 6-min walk distance, and negatively with modified Medical Research Council scores. Conclusion: Physical inactivity is highly prevalent across chronic airways diseases and is consistently associated with established clinical outcome measures. These findings highlight the clinical relevance of objective physical activity assessment and support its consideration within the treatable traits framework as part of routine disease evaluation and management.
- Open Access
- 25 December 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69747
Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study
Background: The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. Objective: This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. Methods: A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. Results: A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. Conclusions: This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. Trial Registration: ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025
- 25 December 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69747
Open AccessProviding Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study
Background: The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. Objective: This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. Methods: A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. Results: A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. Conclusions: This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. Trial Registration: ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025
- Open Access
- 16 January 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Pneumonia and parapneumonic pleural effusions in adults with cystic fibrosis
Cystic fibrosis (CF) is caused by an absence or dysfunction of the transmembrane conductance regulator (CFTR) protein, an anion channel exchanging chloride and bicarbonate across epithelia. In the airways, this ionic imbalance results in dehydrated airway surface liquid, tenacious secretions and impaired mucociliary clearance, leading to endobronchial infections, inflammation and progressive lung damage [1].
- 16 January 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Open AccessPneumonia and parapneumonic pleural effusions in adults with cystic fibrosis
Cystic fibrosis (CF) is caused by an absence or dysfunction of the transmembrane conductance regulator (CFTR) protein, an anion channel exchanging chloride and bicarbonate across epithelia. In the airways, this ionic imbalance results in dehydrated airway surface liquid, tenacious secretions and impaired mucociliary clearance, leading to endobronchial infections, inflammation and progressive lung damage [1].
- Open Access
- 6 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study (Preprint)
BACKGROUND The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. OBJECTIVE This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. METHODS A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. RESULTS A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. CONCLUSIONS This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. CLINICALTRIAL ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025
- 6 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessProviding Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study (Preprint)
BACKGROUND The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. OBJECTIVE This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. METHODS A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. RESULTS A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. CONCLUSIONS This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. CLINICALTRIAL ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025
- Open Access
- 31 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 734-746
Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab
Background: Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear. Additionally, the impact of pulmonary and extrapulmonary comorbidities on the ability to meet remission is poorly understood.Methods: Clinical outcomes including remission of SEA with benralizumab at 1 and 2 years were assessed retrospectively in a real‐world UK multi‐centre severe asthma cohort. The presence of clinically relevant pulmonary and extrapulmonary comorbidities associated with respiratory symptoms was recorded. Analyses to identify factors associated with the ability to meet remission were performed.Results: In total, 276 patients with SEA treated with benralizumab including 113 patients who had switched from a previous biologic to benralizumab were included. Overall, clinical remission was met in 17% (n = 31/186) and 32% (n = 43/133) of patients at 1 and 2 years, respectively. This increased to 28% at 1 year and 49% at 2 years once patients with pulmonary and/or extrapulmonary comorbidities were excluded. Body mass index (BMI) and maintenance OCS (mOCS) use demonstrated a negative association with clinical remission at 1 (BMI: OR: 0.89, 95% CI: 0.82–0.96, p < 0.01; mOCS: OR: 0.94, 95% CI: 0.89–0.99, p < 0.05) and 2 years (BMI: OR: 0.93, 95% CI: 0.87–0.99, p < 0.05; mOCS: OR: 0.95, 95% CI: 0.89–0.99, p < 0.05).Conclusions: In this long‐term, real‐world study, patients with SEA demonstrated the ability to meet and sustain clinical remission when treated with benralizumab. The presence of comorbidities including obesity, which are known to be independently associated with respiratory symptoms, reduced the likelihood of meeting clinical remission.
- 31 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 734-746
Open AccessOvercoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab
Background: Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear. Additionally, the impact of pulmonary and extrapulmonary comorbidities on the ability to meet remission is poorly understood.Methods: Clinical outcomes including remission of SEA with benralizumab at 1 and 2 years were assessed retrospectively in a real‐world UK multi‐centre severe asthma cohort. The presence of clinically relevant pulmonary and extrapulmonary comorbidities associated with respiratory symptoms was recorded. Analyses to identify factors associated with the ability to meet remission were performed.Results: In total, 276 patients with SEA treated with benralizumab including 113 patients who had switched from a previous biologic to benralizumab were included. Overall, clinical remission was met in 17% (n = 31/186) and 32% (n = 43/133) of patients at 1 and 2 years, respectively. This increased to 28% at 1 year and 49% at 2 years once patients with pulmonary and/or extrapulmonary comorbidities were excluded. Body mass index (BMI) and maintenance OCS (mOCS) use demonstrated a negative association with clinical remission at 1 (BMI: OR: 0.89, 95% CI: 0.82–0.96, p < 0.01; mOCS: OR: 0.94, 95% CI: 0.89–0.99, p < 0.05) and 2 years (BMI: OR: 0.93, 95% CI: 0.87–0.99, p < 0.05; mOCS: OR: 0.95, 95% CI: 0.89–0.99, p < 0.05).Conclusions: In this long‐term, real‐world study, patients with SEA demonstrated the ability to meet and sustain clinical remission when treated with benralizumab. The presence of comorbidities including obesity, which are known to be independently associated with respiratory symptoms, reduced the likelihood of meeting clinical remission.
- Open Access
- 31 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0304555
Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p<0.0013, p = 0.0476), IL-6 (p = 0.0109, p = 0.0216) and TNF (p = 0.0028, p = 0.0033) levels in CF serum and following PBMCs stimulation respectively. The corresponding mRNA levels were also found to be reduced in stimulated PBMCs, as well as reduced ASC specks and caspase-1 levels, indicative of NLRP3-mediated production of pro-inflammatory cytokines, IL-1β and IL-18. While ETI therapy is highly effective at reducing sweat chloride and improving lung function, it also displays potent anti-inflammatory properties, which are likely to contribute to improved long-term clinical outcomes.
- 31 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0304555
Open AccessAnti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p<0.0013, p = 0.0476), IL-6 (p = 0.0109, p = 0.0216) and TNF (p = 0.0028, p = 0.0033) levels in CF serum and following PBMCs stimulation respectively. The corresponding mRNA levels were also found to be reduced in stimulated PBMCs, as well as reduced ASC specks and caspase-1 levels, indicative of NLRP3-mediated production of pro-inflammatory cytokines, IL-1β and IL-18. While ETI therapy is highly effective at reducing sweat chloride and improving lung function, it also displays potent anti-inflammatory properties, which are likely to contribute to improved long-term clinical outcomes.